Barclays PLC Cor Medix Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Cor Medix Inc. stock. As of the latest transaction made, Barclays PLC holds 105,602 shares of CRMD stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,602

Previous 77,870 35.61%

Holding current value

$1.09 Million

Previous $629,000 35.93%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$8.1 - $13.59 $224,629 - $376,877	27,732 Added 35.61%	105,602 $855,000
Q3 2024 Nov 15, 2024	SELL	$3.64 - $8.23 $306,204 - $692,324	-84,122 Reduced 51.93%	77,870 $629,000
Q2 2024 Aug 14, 2024	SELL	$4.08 - $6.39 $80,604 - $126,240	-19,756 Reduced 10.87%	161,992 $702,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.24 $108,480 - $156,447	-36,898 Reduced 16.88%	181,748 $771,000
Q4 2023 Feb 15, 2024	BUY	$3.0 - $4.01 $198,954 - $265,935	66,318 Added 43.54%	218,646 $822,000
Q3 2023 Nov 07, 2023	BUY	$3.6 - $4.46 $1,015 - $1,257	282 Added 0.19%	152,328 $564,000
Q2 2023 Aug 03, 2023	SELL	$3.94 - $5.8 $45,219 - $66,566	-11,477 Reduced 7.02%	152,046 $603,000
Q1 2023 May 04, 2023	BUY	$3.22 - $4.61 $65,659 - $94,002	20,391 Added 14.25%	163,523 $677,000
Q3 2022 Nov 03, 2022	SELL	$2.82 - $7.52 $1.71 Million - $4.56 Million	-606,868 Reduced 80.92%	143,132 $405,000
Q2 2022 Aug 12, 2022	BUY	$2.73 - $5.61 $2.03 Million - $4.17 Million	743,846 Added 12087.2%	750,000 $3.02 Million
Q1 2022 May 16, 2022	SELL	$3.83 - $6.24 $152,594 - $248,614	-39,842 Reduced 86.62%	6,154 $34,000
Q4 2021 Feb 14, 2022	BUY	$4.47 - $5.56 $136,375 - $169,630	30,509 Added 197.0%	45,996 $209,000
Q3 2021 Nov 09, 2021	SELL	$4.46 - $7.11 $16,448 - $26,221	-3,688 Reduced 19.23%	15,487 $72,000
Q2 2021 Aug 13, 2021	SELL	$6.05 - $10.09 $48,690 - $81,204	-8,048 Reduced 29.56%	19,175 $131,000
Q1 2021 May 13, 2021	BUY	$6.84 - $17.58 $116,129 - $298,473	16,978 Added 165.72%	27,223 $272,000
Q4 2020 Feb 11, 2021	SELL	$5.0 - $9.15 $18,315 - $33,516	-3,663 Reduced 26.34%	10,245 $76,000
Q3 2020 Nov 12, 2020	SELL	$3.96 - $6.15 $1,089 - $1,691	-275 Reduced 1.94%	13,908 $84,000
Q2 2020 Aug 12, 2020	BUY	$3.08 - $6.56 $17,608 - $37,503	5,717 Added 67.53%	14,183 $89,000
Q1 2020 May 13, 2020	SELL	$2.35 - $7.08 $39,773 - $119,829	-16,925 Reduced 66.66%	8,466 $30,000
Q4 2019 Feb 10, 2020	BUY	$4.96 - $7.75 $66,964 - $104,632	13,501 Added 113.55%	25,391 $185,000
Q3 2019 Nov 14, 2019	SELL	$6.38 - $9.69 $26,419 - $40,126	-4,141 Reduced 25.83%	11,890 $75,000
Q2 2019 Aug 14, 2019	SELL	$5.93 - $10.57 $94,684 - $168,771	-15,967 Reduced 49.9%	16,031 $143,000
Q1 2019 May 15, 2019	BUY	$6.95 - $13.25 $222,386 - $423,973	31,998 New	31,998 $302,000

Others Institutions Holding CRMD

# of Institutions

123

Shares Held

18.6M

Call Options Held

134K

Put Options Held

441K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $427M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account